Landos Biopharma, Inc.
NLRX1 LIGANDS
Last updated:
Abstract:
Provided are compounds that target the nucleotide-binding oligomerization domain, leucine rich repeat containing X1 (NLRX1) pathway. The compounds can be used to treat multiple conditions, including inflammatory, immune-mediated, and/or chronic inflammatory gastrointestinal diseases; systemic immune-mediated diseases; cancers; and infectious diseases.
Status:
Application
Type:
Utility
Filling date:
1 May 2020
Issue date:
13 Aug 2020